Cancer drug combo study halted early – what we know
NCT ID NCT03446040
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 36 times
Summary
This early-stage study tested a new drug (BMS-986258) alone or with another immunotherapy (nivolumab) in people with advanced solid tumors like lung, kidney, or breast cancer. The main goal was to check safety and side effects. The study was terminated early, so results are limited. It involved 92 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Local Institution - 0002
Germantown, Tennessee, 38138, United States
-
Local Institution - 0004
Los Angeles, California, 90033, United States
-
Local Institution - 0005
Pittsburgh, Pennsylvania, 15232, United States
-
Local Institution - 0006
Los Angeles, California, 90033, United States
-
Local Institution - 0007
Aurora, Colorado, 80045, United States
-
Local Institution - 0008
Chuo-ku, Tokyo, 1040045, Japan
-
Local Institution - 0009
Kobe, Hyōgo, 6500017, Japan
-
Local Institution - 0010
Grand Rapids, Michigan, 49546, United States
-
Local Institution - 0012
Lebanon, New Hampshire, 03756, United States
-
Local Institution - 0013
Westmead, New South Wales, 2145, Australia
-
Local Institution - 0014
Edmonton, Alberta, T6X 1E8, Canada
-
Local Institution - 0015
Melbourne, Victoria, 3084, Australia
-
Local Institution - 0016
Cincinnati, Ohio, 45267, United States
-
Local Institution - 0018
Ann Arbor, Michigan, 48109-5912, United States
-
Local Institution - 0019
Vancouver, British Columbia, V5Z 4E6, Canada
-
University Of Iowa Hospitals And Clinics
Iowa City, Iowa, 52242, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.